Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Ovid Therapeutics (OVID) Shares Outstanding (2020 - 2025)

Ovid Therapeutics (OVID) has disclosed Shares Outstanding for 3 consecutive years, with $70.5 million as the latest value for Q3 2022.

  • For the quarter ending Q3 2022, Shares Outstanding fell 100.0% year-over-year to $1250.0, compared with a TTM value of $1250.0 through Sep 2022, down 100.0%, and an annual FY2021 reading of $1250.0, down 61.54% over the prior year.
  • Shares Outstanding was $70.5 million for Q3 2022 at Ovid Therapeutics, up from $1250.0 in the prior quarter.
  • Across five years, Shares Outstanding topped out at $70.4 million in Q1 2022 and bottomed at $1250.0 in Q1 2021.
  • Average Shares Outstanding over 3 years is $34.9 million, with a median of $54.8 million recorded in 2020.
  • Peak annual rise in Shares Outstanding hit 5637250.8% in 2022, while the deepest fall reached 100.0% in 2022.
  • Year by year, Shares Outstanding stood at $3250.0 in 2020, then surged by 2164974.22% to $70.4 million in 2021, then increased by 0.14% to $70.5 million in 2022.
  • Business Quant data shows Shares Outstanding for OVID at $1250.0 in Q3 2022, $1250.0 in Q2 2022, and $70.4 million in Q1 2022.